

Special Issue

Innovations in Kidney Disease: From Pathogenesis to Therapy

Message from the Guest Editor

Kidney disease represents a major global health burden, characterized by complex pathophysiology and a frequently progressive course toward end-stage renal disease. Despite advances in care, there remains an urgent need for innovative strategies to enable earlier detection, slow disease progression, and develop effective treatments. This Special Issue, "Innovations in Kidney Disease: From Pathogenesis to Therapy", is dedicated to showcasing cutting-edge research that bridges this translational gap. We welcome contributions that investigate the molecular and cellular mechanisms underlying kidney injury, identify novel diagnostic and prognostic biomarkers, and evaluate emerging therapeutic modalities. Topics of interest include, but are not limited to, targeted biologics, cell-based therapies, nanomedicine-based therapies, RNA interference techniques, and drug repurposing. Our goal is to compile high-impact original research articles and reviews that showcase the interdisciplinary efforts driving the field forward, with the ultimate aim of transforming patient outcomes through precision medicine and innovative therapeutic interventions.

Guest Editor

Dr. Yupei Li

West China Hospital of Sichuan University, Guoxue Alley No. 37,
Chengdu, China

Deadline for manuscript submissions

31 January 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/256877

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).